[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @yusufhameed Yusuf Hameed, MD Yusuf Hameed, MD posts on X about $sgmo, $pgen, $beam, $qure the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::47121634/interactions)  - X Week XXXXX +24% - X Month XXXXXX -XX% - X Months XXXXXXX +37% - X Year XXXXXXX +66% ### Mentions: XX [#](/creator/twitter::47121634/posts_active)  - X Week XX +36% - X Month XX +1% - X Months XXX +41% - X Year XXX +20% ### Followers: XXXXX [#](/creator/twitter::47121634/followers)  - X Week XXXXX +0.40% - X Month XXXXX +1.50% - X Months XXXXX +14% - X Year XXXXX +15% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::47121634/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XX% [cryptocurrencies](/list/cryptocurrencies) XXXXX% [finance](/list/finance) XXXX% [automotive brands](/list/automotive-brands) XXXX% [celebrities](/list/celebrities) XXXX% **Social topic influence** [$sgmo](/topic/$sgmo) #1, [$pgen](/topic/$pgen) #5, [$beam](/topic/$beam) #25, [$qure](/topic/$qure) #22, [$vrtx](/topic/$vrtx) #13, [$crsp](/topic/$crsp) #14, [$edit](/topic/$edit) #2, [$ntla](/topic/$ntla) #11, [$lly](/topic/$lly) #105, [reduce](/topic/reduce) XXXX% **Top accounts mentioned or mentioned by** [@abc](/creator/undefined) [@nbcnews](/creator/undefined) [@cbsnews](/creator/undefined) [@foxnews](/creator/undefined) [@newsnation](/creator/undefined) [@cnn](/creator/undefined) [@billackman](/creator/undefined) [@elonmusk](/creator/undefined) [@potus](/creator/undefined) [@senschumer](/creator/undefined) [@sandymacrae23](/creator/undefined) [@drmakaryfda](/creator/undefined) [@sangamotx](/creator/undefined) [@nycmayor](/creator/undefined) [@vp](/creator/undefined) [@senfettermanpa](/creator/undefined) [@stopantisemites](/creator/undefined) [@jimcramer](/creator/undefined) [@harvard](/creator/undefined) [@nyuniversity](/creator/undefined) **Top assets mentioned** [BEAM (BEAM)](/topic/$beam) [uniQure N.V. (QURE)](/topic/$qure) [Vertex Protocol (VRTX)](/topic/$vrtx) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [Eli Lilly and Company (LLY)](/topic/$lly) [Pfizer, Inc. (PFE)](/topic/$pfe) [Biogen Inc (BIIB)](/topic/$biib) [Novartis AG (NVS)](/topic/$nvs) ### Top Social Posts Top posts by engagements in the last XX hours "I'd peg it at 10-20%decent on merits but drowned out by flashier candidates. If $SGMO touts U.S. manufacturing or affordability it could jump to 30-40%. The fact that they can't nail down a partnership after talking about it for XX months says it all @sandymacrae23" [X Link](https://x.com/yusufhameed/status/1995836678809014287) 2025-12-02T12:45Z 1751 followers, 1445 engagements "If ST-503 works it's a $1B drug at least $VRTX needs to partner with $SGMO. It's like Papzimeos for $PGEN hope it works well in humans. These patients need something to help them from terrible debilitating pain" [X Link](https://x.com/yusufhameed/status/1995859616329265597) 2025-12-02T14:16Z 1751 followers, 1206 engagements "$SGMO @DrMakaryFDA stated the agency would prioritize approvals for therapies that "reduce downstream healthcare spending" explicitly citing those that avert surgeries transfusions or ongoing treatments. Biotech analysts on X interpreted this as a boon for gene therapies like Sangamo's ST-920 for Fabry disease which eliminates the need for ERT by enabling sustained enzyme production after one dosepotentially saving billions in lifetime costs compared to ERT's recurring expenses. Makary's comments align with his 100-day FDA statement (July 2025) where he removed restrictions on certain gene" [X Link](https://x.com/yusufhameed/status/1996888038601802214) 2025-12-05T10:23Z 1751 followers, 2536 engagements "$PFE $SGMO Sangamo's gene therapy showed strong Phase X data (superior to standard prophylaxis with durable FVIII expression) potentially offering a more transformative one-and-done alternative for hemophilia A patients without inhibitors. However it's not "better" in practice yetHympavzi is approved accessible and addresses a wider population (including inhibitors and hemophilia B) while gene therapies like giroctocogene face commercialization headwinds (e.g. patient/physician hesitancy high costs and Pfizer's pivot to non-gene options like Hympavzi). Sangamo is optimistic about partnering" [X Link](https://x.com/yusufhameed/status/1998005298066251930) 2025-12-08T12:22Z 1753 followers, 2171 engagements "@SangamoTx $SGMO gets very little respect @sandymacrae23 @jimcramer. There's nothing really out there that works well spinal cords stimulators ok but we need to attack the root of the problem (dorsal root ganglion receptors) $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY $RHHBY $BIIB $VRTX" [X Link](https://x.com/yusufhameed/status/1995863827825754282) 2025-12-02T14:33Z 1753 followers, XXX engagements "Back to reality with only 1M shares but nice to be above .50 party could be short-lived. $SGMO $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY" [X Link](https://x.com/yusufhameed/status/1996958089623298383) 2025-12-05T15:01Z 1753 followers, 1149 engagements "@Yale @Harvard @Columbia @nyuniversity havens for Palestinian bullies College not a safe haven if Jewish @StopAntisemites @usedgov" [X Link](https://x.com/yusufhameed/status/1998006192967184453) 2025-12-08T12:26Z 1753 followers, XX engagements "$NVS Novartis receives FDA approval for Itvisma the only gene replacement therapy for children two years and older teens and adults with spinal muscular atrophy (SMA). This will great for $SGMO intrathecal injection of ST-503 for pain if results successful. It is designed for a one-time intrathecal (spinal) injection making it a potential one-and-done therapy for conditions where current treatments (e.g. opioids anticonvulsants) offer limited efficacy or carry significant risks" [X Link](https://x.com/yusufhameed/status/1993295703204827545) 2025-11-25T12:28Z 1750 followers, 1399 engagements "It's a reminder of $SGMO's tech edge in a $50B+ gene editing market. Zinc fingers are more compact/deliverable than CRISPR (AAV-friendly) positioning them for brain diseases where others struggle. If this leads to a deal (like their $1.4B Eli Lilly neuro capsid pact) it could be transformative" [X Link](https://x.com/yusufhameed/status/1994101779147960794) 2025-11-27T17:51Z 1749 followers, 3528 engagements "Why no partner yet for $SGMO's ST-920 Fabry gene therapy X. Sangamo wants $200-300M+ upfront; partners say no way for a rare disease asset X. Sanofi/Takeda fear cannibalization of their ERT cash cows X. Cash runway X quarter partners scared of dilution & execution risk Strong data but tough economics. $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY $RHHBY $VRTX $TAK @DrMakaryFDA @SecKennedy @adamfeuerstein" [X Link](https://x.com/yusufhameed/status/1994337957486940310) 2025-11-28T09:29Z 1749 followers, 1215 engagements "@Justin48413386 @Franca_ole @sandymacrae23 Unfortunately @SangamoTx has diluted the crap out of $SGMO" [X Link](https://x.com/yusufhameed/status/1995867550790681075) 2025-12-02T14:48Z 1749 followers, XXX engagements "$QURE uniQure Provides Regulatory Update on AMT-130 for Huntingtons Disease down XX% in premarket trading" [X Link](https://x.com/yusufhameed/status/1996559816492536287) 2025-12-04T12:38Z 1748 followers, XXX engagements "Unlike Sangamo $QURE's November FDA news introduced significant uncertainty to its flagship program eroding recent gains and highlighting execution risks in using early data/external controls for approval. In contrast $SGMO has built positive regulatory tailwinds in December (Fast Track) and November (BLA acceptance) positioning it for a potential 2026 Fabry launch without comparable drama. While QURE has superior cash and analyst backing (potentially higher reward if it rebounds) Sangamo's situation feels more stable and "better" right now for risk-averse investorslower downside from" [X Link](https://x.com/yusufhameed/status/1996561839988040074) 2025-12-04T12:46Z 1751 followers, 2259 engagements "Unfortunately it's too late for Jasmine Carpio. 19-year-old undocumented immigrant Eduardo Parra-Corral allegedly drove a Ford Mustang over XXX mph while intoxicated ran a red light in Greeley Colorado and fatally struck 27-year-old Jasmine Faith Carpio's Subaru; she succumbed to injuries five days later per Greeley Police Department reports and Weld County Coroner's confirmation. Parra-Corral faced initial charges of vehicular assault driving without a license and underage alcohol possession later upgraded to vehicular homicide; ICE detained him on November XX and deported him to Mexico on" [X Link](https://x.com/yusufhameed/status/1996919732176343191) 2025-12-05T12:28Z 1748 followers, XXX engagements "When I worked @Wendys many moons ago we told the customers to wait and we could make another batch in 5-8 minutes if they wanted to wait. @ChickfilA should talk to that manager" [X Link](https://x.com/yusufhameed/status/1996959832755023895) 2025-12-05T15:08Z 1749 followers, XX engagements "Another fisherman's boat is ruined @DNC @RNC @SenSchumer @LeaderJohnThune @ABC @NBCNews @CBSNews @CNN @FoxNews @NewsNation @tomcostellonbc @JoeSquawk @SecDuffy @elonmusk" [X Link](https://x.com/yusufhameed/status/1997117673126142387) 2025-12-06T01:35Z 1748 followers, XXX engagements "Pamela Smith who has served as Chief of the Metropolitan Police Department (MPD) since July 2023 announced her resignation on December X 2025 effective December XX 2025. In her own words to Axios the decision was personal: "There comes a time when you just know it's time" after XX years in law enforcement and she explicitly stated that recent federal scrutiny did not influence it" [X Link](https://x.com/yusufhameed/status/1998007230067507291) 2025-12-08T12:30Z 1751 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@yusufhameed Yusuf Hameed, MD
Yusuf Hameed, MD posts on X about $sgmo, $pgen, $beam, $qure the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +24%
- X Month XXXXXX -XX%
- X Months XXXXXXX +37%
- X Year XXXXXXX +66%
Mentions: XX #
- X Week XX +36%
- X Month XX +1%
- X Months XXX +41%
- X Year XXX +20%
Followers: XXXXX #
- X Week XXXXX +0.40%
- X Month XXXXX +1.50%
- X Months XXXXX +14%
- X Year XXXXX +15%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XX% cryptocurrencies XXXXX% finance XXXX% automotive brands XXXX% celebrities XXXX%
Social topic influence $sgmo #1, $pgen #5, $beam #25, $qure #22, $vrtx #13, $crsp #14, $edit #2, $ntla #11, $lly #105, reduce XXXX%
Top accounts mentioned or mentioned by @abc @nbcnews @cbsnews @foxnews @newsnation @cnn @billackman @elonmusk @potus @senschumer @sandymacrae23 @drmakaryfda @sangamotx @nycmayor @vp @senfettermanpa @stopantisemites @jimcramer @harvard @nyuniversity
Top assets mentioned BEAM (BEAM) uniQure N.V. (QURE) Vertex Protocol (VRTX) CRISPR Therapeutics AG (CRSP) Intellia Therapeutics, Inc (NTLA) Eli Lilly and Company (LLY) Pfizer, Inc. (PFE) Biogen Inc (BIIB) Novartis AG (NVS)
Top Social Posts
Top posts by engagements in the last XX hours
"I'd peg it at 10-20%decent on merits but drowned out by flashier candidates. If $SGMO touts U.S. manufacturing or affordability it could jump to 30-40%. The fact that they can't nail down a partnership after talking about it for XX months says it all @sandymacrae23"
X Link 2025-12-02T12:45Z 1751 followers, 1445 engagements
"If ST-503 works it's a $1B drug at least $VRTX needs to partner with $SGMO. It's like Papzimeos for $PGEN hope it works well in humans. These patients need something to help them from terrible debilitating pain"
X Link 2025-12-02T14:16Z 1751 followers, 1206 engagements
"$SGMO @DrMakaryFDA stated the agency would prioritize approvals for therapies that "reduce downstream healthcare spending" explicitly citing those that avert surgeries transfusions or ongoing treatments. Biotech analysts on X interpreted this as a boon for gene therapies like Sangamo's ST-920 for Fabry disease which eliminates the need for ERT by enabling sustained enzyme production after one dosepotentially saving billions in lifetime costs compared to ERT's recurring expenses. Makary's comments align with his 100-day FDA statement (July 2025) where he removed restrictions on certain gene"
X Link 2025-12-05T10:23Z 1751 followers, 2536 engagements
"$PFE $SGMO Sangamo's gene therapy showed strong Phase X data (superior to standard prophylaxis with durable FVIII expression) potentially offering a more transformative one-and-done alternative for hemophilia A patients without inhibitors. However it's not "better" in practice yetHympavzi is approved accessible and addresses a wider population (including inhibitors and hemophilia B) while gene therapies like giroctocogene face commercialization headwinds (e.g. patient/physician hesitancy high costs and Pfizer's pivot to non-gene options like Hympavzi). Sangamo is optimistic about partnering"
X Link 2025-12-08T12:22Z 1753 followers, 2171 engagements
"@SangamoTx $SGMO gets very little respect @sandymacrae23 @jimcramer. There's nothing really out there that works well spinal cords stimulators ok but we need to attack the root of the problem (dorsal root ganglion receptors) $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY $RHHBY $BIIB $VRTX"
X Link 2025-12-02T14:33Z 1753 followers, XXX engagements
"Back to reality with only 1M shares but nice to be above .50 party could be short-lived. $SGMO $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY"
X Link 2025-12-05T15:01Z 1753 followers, 1149 engagements
"@Yale @Harvard @Columbia @nyuniversity havens for Palestinian bullies College not a safe haven if Jewish @StopAntisemites @usedgov"
X Link 2025-12-08T12:26Z 1753 followers, XX engagements
"$NVS Novartis receives FDA approval for Itvisma the only gene replacement therapy for children two years and older teens and adults with spinal muscular atrophy (SMA). This will great for $SGMO intrathecal injection of ST-503 for pain if results successful. It is designed for a one-time intrathecal (spinal) injection making it a potential one-and-done therapy for conditions where current treatments (e.g. opioids anticonvulsants) offer limited efficacy or carry significant risks"
X Link 2025-11-25T12:28Z 1750 followers, 1399 engagements
"It's a reminder of $SGMO's tech edge in a $50B+ gene editing market. Zinc fingers are more compact/deliverable than CRISPR (AAV-friendly) positioning them for brain diseases where others struggle. If this leads to a deal (like their $1.4B Eli Lilly neuro capsid pact) it could be transformative"
X Link 2025-11-27T17:51Z 1749 followers, 3528 engagements
"Why no partner yet for $SGMO's ST-920 Fabry gene therapy X. Sangamo wants $200-300M+ upfront; partners say no way for a rare disease asset X. Sanofi/Takeda fear cannibalization of their ERT cash cows X. Cash runway X quarter partners scared of dilution & execution risk Strong data but tough economics. $CRSP $EDIT $BEAM $NTLA $PGEN $QURE $LLY $RHHBY $VRTX $TAK @DrMakaryFDA @SecKennedy @adamfeuerstein"
X Link 2025-11-28T09:29Z 1749 followers, 1215 engagements
"@Justin48413386 @Franca_ole @sandymacrae23 Unfortunately @SangamoTx has diluted the crap out of $SGMO"
X Link 2025-12-02T14:48Z 1749 followers, XXX engagements
"$QURE uniQure Provides Regulatory Update on AMT-130 for Huntingtons Disease down XX% in premarket trading"
X Link 2025-12-04T12:38Z 1748 followers, XXX engagements
"Unlike Sangamo $QURE's November FDA news introduced significant uncertainty to its flagship program eroding recent gains and highlighting execution risks in using early data/external controls for approval. In contrast $SGMO has built positive regulatory tailwinds in December (Fast Track) and November (BLA acceptance) positioning it for a potential 2026 Fabry launch without comparable drama. While QURE has superior cash and analyst backing (potentially higher reward if it rebounds) Sangamo's situation feels more stable and "better" right now for risk-averse investorslower downside from"
X Link 2025-12-04T12:46Z 1751 followers, 2259 engagements
"Unfortunately it's too late for Jasmine Carpio. 19-year-old undocumented immigrant Eduardo Parra-Corral allegedly drove a Ford Mustang over XXX mph while intoxicated ran a red light in Greeley Colorado and fatally struck 27-year-old Jasmine Faith Carpio's Subaru; she succumbed to injuries five days later per Greeley Police Department reports and Weld County Coroner's confirmation. Parra-Corral faced initial charges of vehicular assault driving without a license and underage alcohol possession later upgraded to vehicular homicide; ICE detained him on November XX and deported him to Mexico on"
X Link 2025-12-05T12:28Z 1748 followers, XXX engagements
"When I worked @Wendys many moons ago we told the customers to wait and we could make another batch in 5-8 minutes if they wanted to wait. @ChickfilA should talk to that manager"
X Link 2025-12-05T15:08Z 1749 followers, XX engagements
"Another fisherman's boat is ruined @DNC @RNC @SenSchumer @LeaderJohnThune @ABC @NBCNews @CBSNews @CNN @FoxNews @NewsNation @tomcostellonbc @JoeSquawk @SecDuffy @elonmusk"
X Link 2025-12-06T01:35Z 1748 followers, XXX engagements
"Pamela Smith who has served as Chief of the Metropolitan Police Department (MPD) since July 2023 announced her resignation on December X 2025 effective December XX 2025. In her own words to Axios the decision was personal: "There comes a time when you just know it's time" after XX years in law enforcement and she explicitly stated that recent federal scrutiny did not influence it"
X Link 2025-12-08T12:30Z 1751 followers, XXX engagements